1.Translation using collaborative translation protocols and initial validation of the Filipino version of stroke specific quality of life scale for stroke survivors.
Angelica Marie V. MANDARIO ; Gerald Neil Sj. MANALO ; Marlo Eduardo M. MANALO ; Jann Marielle M. MANGALI ; Erwin T. MANIPOL ; Christine Beatrix Y. MANALO ; Maria Minerva P. CALIMAG ; Wennielyn F. FAJILAN ; Elenita C. MENDOZA ; John Dale V. TROGO ; Johnny K. LOKIN
Journal of Medicine University of Santo Tomas 2025;9(S1):3-15
METHODOLOGY
A descriptive, cross-sectional design was utilized, involving the translation of the SS-QOL from English to Filipino through Collaborative Translation Protocols, which centered on group consensus. Three Filipino language experts rigorously evaluated the initial translation for linguistic and cultural appropriateness. To assess content and face validity, an expert committee of three neurology consultants provided ratings, which were analyzed using the item-level content validity index (i-CVI). Subsequently, a pilot testing phase was conducted with 10 stroke survivors recruited via purposeful sampling in Metro Manila to evaluate the SS-QOL-Filipino’s clarity, layout, understandability and answerability, while also measuring the intraclass correlation coefficient (ICC) to assess consistency and agreement among items
RESULTSThis study successfully developed a stroke-specific HRQOL tool for the Philippines, addressing a critical need for objective measures in patient-centered care. The use of Collaborative Translation Protocols ensured the questionnaire’s conceptual, linguistic and cultural equivalence, incorporating nuances specific to the Filipino context in areas like eating habits, emotional expressions and technological terms. The high face and content validity, coupled with strong consistency and high understandability observed during pilot testing underscore the SS-QOL-Filipino’s suitability for the target population, positioning it as a valuable instrument for both clinical practice and research.
CONCLUSIONThe SS-QOL scale was successfully translated into Filipino using Collaborative Translation Protocols and rigorously validated. The SS-QOL-Filipino version demonstrates high content and face validity, strong consistency and excellent understandability and answerability, affirming its status as a reliable and appropriate outcome measure for assessing the QOL among stroke patients in Metro Manila.
Human ; Male ; Female ; Middle Aged: 45-64 Yrs Old ; Aged: 65-79 Yrs Old ; Adult: 25-44 Yrs Old ; Life ; Quality Of Life ; Stroke ; Survivors
2.Quality of care among patients with acute heart failure at the emergency room and adherence of physicians at the University of the Philippines – Philippine General Hospital to the division of cardiovascular medicine – heart failure pathway:A retrospective cohort study.
Mark John D. SABANDO ; Felix Eduardo R. PUNZALAN ; Frances Dominique V. HO ; Tam Adrian P. AYA-AY ; Kevin Paul Da. ENRIQUEZ ; Marie Kirk A. MARAMARA ; Ronald Allan B. RODEROS ; Lauren Kay M. EVANGELISTA
Acta Medica Philippina 2025;60(2):22-32
OBJECTIVES
Clinical pathways (CPs) ensure adherence to heart failure (HF) management guidelines. To optimize quality care in a low resource setting, an evidence-based care pathway for the management of acute HF was implemented at the emergency department (ED) of the Philippine General Hospital (PGH), the designated national tertiary hospital and referral center. This study aimed to describe the characteristics of adults with acute HF admitted at the ED and evaluate the quality of care they received, measured using physician adherence to the hospital’s acute heart failure CP.
METHODSThis was a retrospective, descriptive cohort study. We reviewed the inpatient charts of all adult patients with acute HF admitted to the ED of the PGH and referred to the Division of Cardiovascular Medicine between December 1, 2022 and May 31, 2023. Quality of care was assessed based on adherence to quality indicators adapted from routine and conditional order sets detailed in the pathway. Descriptive statistics was utilized to describe patient characteristics, quality of care, and outcomes.
RESULTSTwo hundred thirty-six (236) patients were included, with a mean age of 51.8 years. Majority were male (53.4%); hypertension (61.4%) and ischemic heart disease (53.8%) were the most common comorbidities, and infection the most common precipitant of decompensation (60.6%). There were optimal adherence rates to routine orders, which included referrals to Internal Medicine and Cardiology, baseline vital signs monitoring, fluid intake and output monitoring, chest radiograph, complete blood count, blood urea nitrogen, sodium, potassium, prothrombin time, partial thromboplastin time, arterial blood gas, urinalysis, and N-terminal pro b-type natriuretic peptide. Conditional orders, such as oxygen support, focused echocardiography, thyroid - stimulating hormone, and the use of vasopressors, diuretics, and venous thromboembolism prophylactic agents, were optimally performed when warranted. However, we noted suboptimal adherence to certain resource-intensive conditional orders, such as hourly monitoring of urine output (61.4%), hooking to cardiac monitor (53.8%), and performance of 12-lead ECG within 10 minutes (56.8%). Further, only 43.9% of patients were referred to the intensive care unit. Troponin I, calcium, magnesium, and albumin were ordered in excess.
CONCLUSIONOverall adherence rate of physicians to the hospital’s Acute Heart Failure Pathway was satisfactory. Work is needed to improve adherence to hourly urine output monitoring, consistent hooking to cardiac monitor, and timely performance of 12-lead ECG – an effort that begins with expanding in-hospital diagnostic equipment and human resource supply. We recommend continuous pathway implementation with periodic evaluation and stakeholder feedback to further improve quality of care.
Human ; Male ; Female ; Middle Aged: 45-64 Yrs Old ; Adult ; Albumins ; Blood ; Blood Urea Nitrogen ; Calcium ; Cardiology ; Chart ; Charts ; Cohort Studies ; Critical Care ; Critical Pathways ; Diagnostic Equipment ; Disease ; Diuretics ; Echocardiography ; Electrocardiography ; Emergencies ; Emergency Service, Hospital ; Equipment And Supplies ; Evaluation Studies As Topic ; Feedback ; Heart ; Heart Diseases ; Heart Failure ; Hormones ; Hospitals ; Hospitals, General ; Humans ; Hypertension ; Indicators And Reagents ; Infection ; Infections ; Inpatients ; Intensive Care Units ; Internal Medicine ; Lead ; Magnesium ; Male ; Medicine ; Myocardial Ischemia ; Natriuretic Peptide, Brain ; Natriuretic Peptides ; Nitrogen ; Overall ; Oxygen ; Partial Thromboplastin Time ; Patients ; Peptides ; Philippines ; Physicians ; Potassium ; Prothrombin ; Prothrombin Time ; Quality Of Health Care ; Referral And Consultation ; Sodium ; Statistics ; Tertiary Care Centers ; Thorax ; Thromboembolism ; Thromboplastin ; Thyroid Gland ; Time ; Troponin ; Troponin I ; Universities ; Urea ; Urinalysis ; Urine ; Venous Thromboembolism ; Vital Signs ; Work ; Workforce
3.Electrocardiographic profile of adult patients with coronavirus disease (COVID-19) who were given remdesivir and admitted in the University of the Philippines - Philippine General Hospital (UP-PGH).
Kaye Eunice L. LUSTESTICA ; Felix Eduardo R. PUNZALAN ; Paul Anthony O. ALAD ; Tam Adrian P. AYA-AY ; Zane Oliver M. NELSON III ; Bryan Paul G. RAMIREZ ; Nigel Jeronimo C. SANTOS ; Elmer Jasper B. LLANES
Acta Medica Philippina 2025;60(2):59-65
BACKGROUND AND OBJECTIVE.
Severe Acute Respiratory Syndrome - Coronavirus-2 (SARS-CoV-2) was initially known to affect the respiratory system and has been reported to also involve the cardiovascular system leading to myocardial damage. Remdesivir is one of the approved treatments for COVID-19, wherein viral replication is inhibited by terminating the RNA transcription prematurely. According to studies, the primary electrocardiographic effect of remdesivir in COVID-19 patients are sinus bradycardia and QT prolongation. The use of electrocardiogram (ECG) is an essential diagnostic tool in assessing the electrical conditions of the heart. The objective of this study is to describe the electrocardiographic profile of adult patients with COVID-19 who were given remdesivir and admitted in the University of the Philippines-Philippine General Hospital (UP-PGH). To this date, this is the only study done locally identifying the electrocardiographic profiles of adult patients with COVID-19 who were given remdesivir.
METHODSThis was a retrospective descriptive study involving adult patients with COVID-19 who were given remdesivir and admitted in UP-PGH from June 2021 to June 2022. Demographic profiles and 12-lead ECG done during the hospital admission were gathered. Descriptive statistics was used to summarize the clinical characteristics and the electrocardiographic findings of the patients.
RESULTSThere were 412 confirmed COVID-19 patients who were given remdesivir (mean age 56 years old; female 52%) included in this study. The most common comorbidities were hypertension, diabetes mellitus, and stroke. Majority of the patients had severe (58%) to critical (22%) COVID-19 infection. Most of the patients had sinus rhythm (94%), normal rate (72%), and normal axis (93%). The most common baseline ECG findings were non-specific ST-T wave changes (42%). Some patients had atrioventricular blocks (3.4%), bundle branch blocks (3.6%), prolonged QT interval (1.9%). Among those with repeat 12-L ECG (136 patients) during admission, ECG changes observed were sinus bradycardia (6%), prolonged QT interval (4%), and both (1.5%).
CONCLUSIONBased on this retrospective review, which to our knowledge is the only study done locally investigating the effects of remdesivir on ECG of adult Filipino patients with COVID-19 infection, majority of the patients had sinus rhythm, normal rate, and axis. The most common ECG finding was non-specific ST-T wave changes. This study demonstrated a low incidence of adverse ECG changes that would preclude the administration of remdesivir when indicated. These include sinus bradycardia and QT interval prolongation which did not require further interventions. ECG remains to be useful, low-cost noninvasive tool that can help monitor electrophysiologic adverse events of remdesivir.
4.Electrocardiographic manifestations of hospitalized adult patients with coronavirus disease 19 (COVID-19): UP-PGH DCVM ECG study
Felix Eduardo R. Punzalan ; Paul Anthony O. Alad ; Tam Adrian P. Aya-ay ; Kaye Eunice L. Lustestica ; Nigel Jeronimo C. Santos ; Jaime Alfonso M. Aherrera ; Elmer Jasper B. Llanes ; Giselle G. Gervacio ; Eugenio B. Reyes ; John C. Añ ; onuevo
Acta Medica Philippina 2025;59(Early Access 2025):1-5
BACKGROUND AND OBJECTIVE
COVID-19 has been associated with cardiac injury, often detectable through electrocardiographic (ECG) changes. This study seeks to characterize the cardiovascular and electrocardiographic profiles of adult patients diagnosed with COVID-19.
METHODSThis study included adult patients with confirmed COVID-19 from June 2021 to June 2022. Clinical profiles and 12-lead ECG tracings were obtained from electronic medical records and reviewed independently by three cardiologists. Descriptive analysis was performed to summarize the cardiovascular and electrocardiographic findings in this population.
RESULTSThe study included 998 COVID-19 patients (mean age: 50 years; 53.7% male). The most common comorbidities were hypertension, diabetes, and dyslipidemia. A majority (31.36%) presented with severe COVID-19 infection. The most frequent significant ECG abnormalities observed at admission were sinus tachycardia (22.8%), and atrial fibrillation (11.02%). Additional ischemic findings included ST segment depression (2.91%), T-wave inversion (1.70%), and ST segment elevation (2.71%).
CONCLUSIONThe baseline ECG findings among COVID-19 patients were predominantly normal; however, significant abnormalities were also identified. The most frequent abnormalities included sinus tachycardia, atrial fibrillation, and ischemic changes, all of which may have clinical implications.
Human ; Coronavirus Disease 19 ; Covid-19 ; Electrocardiography ; Atrial Fibrillation
5.Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021
Pojsakorn DANPANICHKUL ; Luis Antonio DÍAZ ; Kanokphong SUPARAN ; Primrose TOTHANARUNGROJ ; Supapitch SIRIMANGKLANURAK ; Thanida AUTTAPRACHA ; Hanna L. BLANEY ; Banthoon SUKPHUTANAN ; Yanfang PANG ; Siwanart KONGARIN ; Francisco IDALSOAGA ; Eduardo FUENTES-LÓPEZ ; Lorenzo LEGGIO ; Mazen NOUREDDIN ; Trenton M. WHITE ; Alexandre LOUVET ; Philippe MATHURIN ; Rohit LOOMBA ; Patrick S. KAMATH ; Jürgen REHM ; Jeffrey V. LAZARUS ; Karn WIJARNPREECHA ; Juan Pablo ARAB
Clinical and Molecular Hepatology 2025;31(2):525-547
Background/Aims:
Alcohol represents a leading burden of disease worldwide, including alcohol use disorder (AUD) and alcohol-related liver disease (ALD). We aim to assess the global burden of AUD, ALD, and alcohol-attributable primary liver cancer between 2000–2021.
Methods:
We registered the global and regional trends of AUD, ALD, and alcohol-related liver cancer using data from the Global Burden of Disease 2021 Study, the largest and most up-to-date global epidemiology database. We estimated the annual percent change (APC) and its 95% confidence interval (CI) to assess changes in age-standardized rates over time.
Results:
In 2021, there were 111.12 million cases of AUD, 3.02 million cases of ALD, and 132,030 cases of alcohol-attributable primary liver cancer. Between 2000 and 2021, there was a 14.66% increase in AUD, a 38.68% increase in ALD, and a 94.12% increase in alcohol-attributable primary liver cancer prevalence. While the age-standardized prevalence rate for liver cancer from alcohol increased (APC 0.59%; 95% confidence interval [CI] 0.52 to 0.67%) over these years, it decreased for ALD (APC –0.71%; 95% CI –0.75 to –0.67%) and AUD (APC –0.90%; 95% CI –0.94 to –0.86%). There was significant variation by region, socioeconomic development level, and sex. During the last years (2019–2021), the prevalence, incidence, and death of ALD increased to a greater extent in females.
Conclusions
Given the high burden of AUD, ALD, and alcohol-attributable primary liver cancer, urgent measures are needed to prevent them at both global and national levels.
6.Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021
Pojsakorn DANPANICHKUL ; Luis Antonio DÍAZ ; Kanokphong SUPARAN ; Primrose TOTHANARUNGROJ ; Supapitch SIRIMANGKLANURAK ; Thanida AUTTAPRACHA ; Hanna L. BLANEY ; Banthoon SUKPHUTANAN ; Yanfang PANG ; Siwanart KONGARIN ; Francisco IDALSOAGA ; Eduardo FUENTES-LÓPEZ ; Lorenzo LEGGIO ; Mazen NOUREDDIN ; Trenton M. WHITE ; Alexandre LOUVET ; Philippe MATHURIN ; Rohit LOOMBA ; Patrick S. KAMATH ; Jürgen REHM ; Jeffrey V. LAZARUS ; Karn WIJARNPREECHA ; Juan Pablo ARAB
Clinical and Molecular Hepatology 2025;31(2):525-547
Background/Aims:
Alcohol represents a leading burden of disease worldwide, including alcohol use disorder (AUD) and alcohol-related liver disease (ALD). We aim to assess the global burden of AUD, ALD, and alcohol-attributable primary liver cancer between 2000–2021.
Methods:
We registered the global and regional trends of AUD, ALD, and alcohol-related liver cancer using data from the Global Burden of Disease 2021 Study, the largest and most up-to-date global epidemiology database. We estimated the annual percent change (APC) and its 95% confidence interval (CI) to assess changes in age-standardized rates over time.
Results:
In 2021, there were 111.12 million cases of AUD, 3.02 million cases of ALD, and 132,030 cases of alcohol-attributable primary liver cancer. Between 2000 and 2021, there was a 14.66% increase in AUD, a 38.68% increase in ALD, and a 94.12% increase in alcohol-attributable primary liver cancer prevalence. While the age-standardized prevalence rate for liver cancer from alcohol increased (APC 0.59%; 95% confidence interval [CI] 0.52 to 0.67%) over these years, it decreased for ALD (APC –0.71%; 95% CI –0.75 to –0.67%) and AUD (APC –0.90%; 95% CI –0.94 to –0.86%). There was significant variation by region, socioeconomic development level, and sex. During the last years (2019–2021), the prevalence, incidence, and death of ALD increased to a greater extent in females.
Conclusions
Given the high burden of AUD, ALD, and alcohol-attributable primary liver cancer, urgent measures are needed to prevent them at both global and national levels.
7.Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021
Pojsakorn DANPANICHKUL ; Luis Antonio DÍAZ ; Kanokphong SUPARAN ; Primrose TOTHANARUNGROJ ; Supapitch SIRIMANGKLANURAK ; Thanida AUTTAPRACHA ; Hanna L. BLANEY ; Banthoon SUKPHUTANAN ; Yanfang PANG ; Siwanart KONGARIN ; Francisco IDALSOAGA ; Eduardo FUENTES-LÓPEZ ; Lorenzo LEGGIO ; Mazen NOUREDDIN ; Trenton M. WHITE ; Alexandre LOUVET ; Philippe MATHURIN ; Rohit LOOMBA ; Patrick S. KAMATH ; Jürgen REHM ; Jeffrey V. LAZARUS ; Karn WIJARNPREECHA ; Juan Pablo ARAB
Clinical and Molecular Hepatology 2025;31(2):525-547
Background/Aims:
Alcohol represents a leading burden of disease worldwide, including alcohol use disorder (AUD) and alcohol-related liver disease (ALD). We aim to assess the global burden of AUD, ALD, and alcohol-attributable primary liver cancer between 2000–2021.
Methods:
We registered the global and regional trends of AUD, ALD, and alcohol-related liver cancer using data from the Global Burden of Disease 2021 Study, the largest and most up-to-date global epidemiology database. We estimated the annual percent change (APC) and its 95% confidence interval (CI) to assess changes in age-standardized rates over time.
Results:
In 2021, there were 111.12 million cases of AUD, 3.02 million cases of ALD, and 132,030 cases of alcohol-attributable primary liver cancer. Between 2000 and 2021, there was a 14.66% increase in AUD, a 38.68% increase in ALD, and a 94.12% increase in alcohol-attributable primary liver cancer prevalence. While the age-standardized prevalence rate for liver cancer from alcohol increased (APC 0.59%; 95% confidence interval [CI] 0.52 to 0.67%) over these years, it decreased for ALD (APC –0.71%; 95% CI –0.75 to –0.67%) and AUD (APC –0.90%; 95% CI –0.94 to –0.86%). There was significant variation by region, socioeconomic development level, and sex. During the last years (2019–2021), the prevalence, incidence, and death of ALD increased to a greater extent in females.
Conclusions
Given the high burden of AUD, ALD, and alcohol-attributable primary liver cancer, urgent measures are needed to prevent them at both global and national levels.
8.The development of an order set for adults admitted for acute heart failure at a National University Hospital in the Philippines
John Vincent U. Magalong ; Felix Eduardo R. Punzalan ; Marie Kirk Patrich A. Maramara ; Frederick Berro B. Rivera ; Zane Oliver O. Nelson ; Bai Sitti Ameerah B. Tago ; Cecileen Anne M. Tuazon ; Ruth Divine D. Agustin ; Lauren Kay M. Evangelista ; Michelle Marie Q. Pipo ; Eugenio B. Reyes ; John C. Anonuevo ; Diana R. Tamondong-lachic
Acta Medica Philippina 2025;59(3):45-56
BACKGROUND AND OBJECTIVES
Heart Failure (HF) remains a major health concern worldwide. In the Philippine General Hospital (PGH), HF is consistently a top cause of mortality and readmissions among adults. The American College of Cardiology (ACC) and European Society of Cardiology (ESC) published guidelines for interventions that improve quality of life and survival, but they are underused and untested for local acceptability. Hospitals overseas used order sets created from these guidelines, which resulted in a considerable decrease in in-hospital mortality and healthcare costs. We aimed to develop an order set for adult patients with acute heart failure (AHF) admitted to the PGH Emergency Department (ED) to improve care outcomes.
METHODSThis study utilized a mixed methods approach to create the AHF order set. ESC and ACC HF guidelines were appraised using the AGREE II tool. Class I interventions for AHF were included in the initial order set. Through focused group discussions (FGD), clinicians and other care team members involved in the management of AHF patients at PGH ED modified and validated the order set. Stakeholders were asked to use online Delphi and FGD to get a consensus on how to amend, approve, and carry out the order given.
RESULTSUpon review of HF guidelines, 29 recommendations on patient monitoring, initial diagnostic, and therapeutic interventions were adopted in the order set. Orders on subspecialty referrals and ED disposition were introduced. The AHF patient was operationally defined in the setting of PGH ED. The clinical orders fit the PGH context, ensuring evidence-based, cost-effective, and accessible care responsiveness to patients’ needs and suitable for local practice. Workflow changes due to COVID-19 were considered. Potential barriers to implementation were identified and addressed. The final order set was adopted for implementation through stakeholder consensus.
CONCLUSIONThe PGH developed and adopted its own AHF order set that is locally applicable and can potentially optimize outcomes of care.
Human ; Quality Of Life ; Critical Pathways ; Quality Improvement
9.Quality of care among post–discharge patients with heart failure with reduced ejection Fraction (HFrEF) at the outpatient department (OPD) of a tertiary center
Kevin Paul Da. Enriquez ; Sherry Mae C. Mondido ; Mark John D. Sabando ; Tam Adrian P. Aya-ay ; Nigel Jeronimo C. Santos ; Ronald Allan B. Roderos ; Bryan Paul G. Ramirez ; Frances Dominique V. Ho ; Lauren Kay M. Evangelsta ; Felix Eduardo R. Punzalan
Acta Medica Philippina 2025;59(10):52-61
BACKGROUND AND OBJECTIVE
Physician adherence to the recommended management of patients with heart failure with reduced ejection fraction (HFrEF) at the outpatient setting is crucial to reduce the burden of subsequent rehospitalization, morbidity, and mortality. Recently updated guidelines recommend early and rapid titration to optimal doses of medications in the first 2 to 6 weeks of discharge. In the absence of local data, our study evaluates physician adherence to guideline-recommended treatment in this setting.
METHODSThis is a retrospective cross-sectional study among post-discharge HFrEF patients at the outpatient department from December 2022 to May 2023 with a follow-up within three months. Clinical profile and treatment were extracted from medical records. Adherence to the 2021 ESC Guidelines Class I recommendations, among eligible patients, is measured as quality indicators. Data are presented using descriptive statistics.
RESULTSA total of 99 patients were included in the study. Overall, adherence to prescription of beta-blockers (94.8%), ACEI/ARNI/ARBs (88.5%), and diuretics (100%) were high. Prescription of mineralocorticoid receptor antagonists (MRA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) were 67% and 57.3%, respectively. Over three months of follow-up, improvement in the quality of care was demonstrated with ACEI/ARNI/ARBs (81.8% to 90.9%), MRA (68.7 to 81.2%), and SGLT2i (58% to 67.7%). Beta-blocker use is consistently high at 97%. In the 3rd month post-discharge, titration to optimal doses was achieved in only 26.4%, 15%, and 6.25% for those on beta-blockers, ACEI/ARNI/ARB, and MRA, respectively. For non-pharmacologic management, referral to HF specialty was made in 30% and cardiac rehabilitation in 22.2%.
CONCLUSIONAmong patients with HFrEF seen at the outpatient, there is good physician adherence to betablockers, ACEI/ARNI/ARBs, and diuretics. MRA and SGLT2i prescription, referral to HF specialty and cardiac rehabilitation, and up-titration to optimal doses of oral medications for HF need improvement. Hospital pathway development and regular performance evaluation will improve initiation, maintenance, and up-titration of appropriate treatment.
Human ; Outpatients
10.Incidence and associated risk factors of hypertension among apparently healthy adult Filipinos in the LIFECARE Philippine cohort study
Elmer Jasper B. Llanes ; Olivia T. Sison ; Felix Eduardo R. Punzalan ; Jose Eduardo Dl Duya ; Nina T. Castillo-carandang ; Wilbert Allan G. Gumatay ; Paulette D. Nacpil-dominguez ; Paul Ferdinand M. Reganit ; Rody G. Sy
Acta Medica Philippina 2025;59(12):19-27
OBJECTIVE
This study aimed to estimate the incidence of hypertension and determine the risk factors for hypertension among apparently healthy adult Filipinos.
METHODSThis observational prospective community-based study included apparently healthy adult individuals aged 20–50 years from the Life Course Study in Cardiovascular Disease Epidemiology (LIFECARE) Philippine cohort at baseline and followed-up after an average of four years. Sociodemographic data, psychosocial stress, and clinical and metabolic profiles were obtained and analyzed. Multivariable Cox regression analysis was performed to identify factors associated with the development of hypertension.
RESULTSA total of 2,089 non-hypertensive participants were included, with 59% women and average age of 35 years (SD = 8.4). The incidence rate of hypertension was 38.1 per 1,000 person-years. The cumulative incidence of hypertension over a mean follow-up time of four years was 15.4% (95% CI = 13.9–17.0%). The risk of incident hypertension was higher among males (aHR=1.3, 95% CI: 1.0–1.8; p=0.044), ≥40 years old (aHR=3.9, 95% CI: 2.6–5.8; pCONCLUSION
The 4-year incidence rate of hypertension among apparently healthy adult Filipinos is high. Increased age, male sex, family history of hypertension, abdominal obesity, and high normal blood pressure were significantly associated with the development of hypertension.
Human ; Hypertension ; Incidence


Result Analysis
Print
Save
E-mail